{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,9]],"date-time":"2026-10-09T23:55:29Z","timestamp":1791590129656,"version":"4.3.4"},"reference-count":40,"publisher":"Oxford University Press (OUP)","issue":"11","license":[{"start":{"date-parts":[[2022,2,15]],"date-time":"2022-02-15T00:00:00Z","timestamp":1644883200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/journals\/pages\/open_access\/funder_policies\/chorus\/standard_publication_model"}],"funder":[{"DOI":"10.13039\/100006483","name":"AbbVie","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100006483","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2022,11,2]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:sec>\n                  <jats:title>Objectives<\/jats:title>\n                  <jats:p>To assess efficacy and safety of biologic therapy (BT) in neurobeh\u00e7et\u2019s disease (NBD) refractory to glucocorticoids and at least one conventional immunosuppressive drug.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Methods<\/jats:title>\n                  <jats:p>Open-label, national, multicentre study. NBD diagnosis was based on the International Consensus Recommendation criteria. Outcome variables were efficacy and safety. Main efficacy outcome was clinical remission. Other outcome variables analysed were glucocorticoid-sparing effect and improvement in laboratory parameters.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Results<\/jats:title>\n                  <jats:p>We studied 41 patients [21 women; age 40.6\u2009(10.8)\u2009years]. Neurological damage was parenchymal (n\u2009=\u200933, 80.5%) and non-parenchymal (n\u2009=\u200917, 41.5%). First BTs used were infliximab (n\u2009=\u200919), adalimumab (n\u2009=\u200914), golimumab (n\u2009=\u20093), tocilizumab (n\u2009=\u20093) and etanercept (n\u2009=\u20092). After 6\u2009months of BT, neurological remission was complete (n\u2009=\u200923, 56.1%), partial (n\u2009=\u200915, 37.6%) and no response (n\u2009=\u20093, 7.3%). In addition, median (IQR) dose of oral prednisone decreased from 60 (30\u201360) mg\/day at the initial visit to 5 (3.8\u201310) mg\/day after 6\u2009months (P\u2009&amp;lt;\u20090.001). It was also the case for mean erythrocyte sedimentation rate [31.5\u2009(25.6)\u201315.3\u2009(11.9)\u2009mm\/1st h, P\u2009=\u20090.011] and median (IQR) C-reactive protein [1.4 (0.2\u201312.8) to 0.3 (0.1\u20133)\u00a0mg\/dl, P\u2009=\u20090.001]. After a mean follow-up of 57.5\u2009months, partial or complete neurological remission persisted in 37 patients (90.2%). BT was switched in 22 cases (53.6%) due to inefficacy (n\u2009=\u200916) or adverse events (AEs) (n\u2009=\u20096) and discontinued due to complete prolonged remission (n\u2009=\u20093) or severe AE (n\u2009=\u20091). Serious AEs were observed in two patients under infliximab treatment.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusions<\/jats:title>\n                  <jats:p>BT appears to be effective and relatively safe in refractory NBD.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1093\/rheumatology\/keac097","type":"journal-article","created":{"date-parts":[[2022,2,11]],"date-time":"2022-02-11T20:11:35Z","timestamp":1644610295000},"page":"4427-4436","source":"Crossref","is-referenced-by-count":13,"title":["Biologic therapy in refractory neurobeh\u00e7et\u2019s\u2002disease: a multicentre study of 41 patients and literature review"],"prefix":"10.1093","volume":"61","author":[{"given":"Alba","family":"Herrero-Morant","sequence":"first","affiliation":[{"name":"Rheumatology, Hospital Universitario Marqu\u00e9s de Valdecilla, IDIVAL, University of Cantabria , Santander"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jos\u00e9 Luis","family":"Mart\u00edn-Varillas","sequence":"additional","affiliation":[{"name":"Rheumatology, Hospital de Sierrallana , Torrelavega"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Santos","family":"Casta\u00f1eda","sequence":"additional","affiliation":[{"name":"Rheumatology, Hospital Universitario La Princesa, IIS-Princesa , Madrid"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Olga","family":"Ma\u00edz","sequence":"additional","affiliation":[{"name":"Rheumatology and Ophthalmology, Hospital Universitario de Donostia , San Sebasti\u00e1n"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7623-057X","authenticated-orcid":false,"given":"Julio","family":"S\u00e1nchez","sequence":"additional","affiliation":[{"name":"Rheumatology, Hospital 12 de Octubre , Madrid"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Norberto","family":"Ortego","sequence":"additional","affiliation":[{"name":"Rheumatology and Internal Medicine, Hospital Universitario Cl\u00ednico San Cecilio , Granada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Enrique","family":"Raya","sequence":"additional","affiliation":[{"name":"Rheumatology and Internal Medicine, Hospital Universitario Cl\u00ednico San Cecilio , Granada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"\u00c1gueda","family":"Prior-Espa\u00f1ol","sequence":"additional","affiliation":[{"name":"Rheumatology, Hospital Universitario Germans Trias i Pujol , Barcelona"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Clara","family":"Moriano","sequence":"additional","affiliation":[{"name":"Rheumatology, Hospital de Le\u00f3n , Le\u00f3n"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rafael B","family":"Melero-Gonz\u00e1lez","sequence":"additional","affiliation":[{"name":"Rheumatology, Complejo Hospitalario de Vigo , Vigo"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jenaro","family":"Gra\u00f1a-Gil","sequence":"additional","affiliation":[{"name":"Rheumatology, Hospital Universitario de A Coru\u00f1a , A Coru\u00f1a"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ana","family":"Urruticoechea-Arana","sequence":"additional","affiliation":[{"name":"Rheumatology, Hospital Can Misses , Ibiza"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"\u00c1ngel","family":"Ramos-Calvo","sequence":"additional","affiliation":[{"name":"Rheumatology, Complejo Hospitalario de Soria , Soria"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marta","family":"Loredo-Mart\u00ednez","sequence":"additional","affiliation":[{"name":"Rheumatology, Hospital Cl\u00ednico Lozano Blesa , Zaragoza"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eva","family":"Salgado-P\u00e9rez","sequence":"additional","affiliation":[{"name":"Rheumatology, Complejo Hospitalario Universitario de Ourense , Ourense"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francisca","family":"Sivera","sequence":"additional","affiliation":[{"name":"Rheumatology, Hospital General Universitario de Elda , Elda"},{"name":"Medicina, Universidad Miguel Hernandez , Elche"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ignacio","family":"Torre","sequence":"additional","affiliation":[{"name":"Rheumatology, Hospital de Basurto , Bilbao"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1614-8064","authenticated-orcid":false,"given":"Javier","family":"Narv\u00e1ez","sequence":"additional","affiliation":[{"name":"Rheumatology, Hospital Bellvitge , Barcelona"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jos\u00e9 Luis","family":"Andreu","sequence":"additional","affiliation":[{"name":"Rheumatology, Hospital Universitario Puerta de Hierro-Majadahonda , Madrid"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Olga","family":"Mart\u00ednez-Gonz\u00e1lez","sequence":"additional","affiliation":[{"name":"Rheumatology, Hospital Cl\u00ednico Universitario de Salamanca , Salamanca"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ricardo G\u00f3mez-de la","family":"Torre","sequence":"additional","affiliation":[{"name":"Internal Medicine, Hospital Universitario Central de Asturias , Oviedo"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sabela","family":"Fern\u00e1ndez-Aguado","sequence":"additional","affiliation":[{"name":"Rheumatology, Hospital Universitario de Cabue\u00f1es , Gij\u00f3n"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Susana","family":"Romero-Yuste","sequence":"additional","affiliation":[{"name":"Rheumatology, Complejo Hospitalario Universitario de Pontevedra , Pontevedra"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"\u00cd\u00f1igo","family":"Gonz\u00e1lez-Maz\u00f3n","sequence":"additional","affiliation":[{"name":"Rheumatology, Hospital Universitario Marqu\u00e9s de Valdecilla, IDIVAL, University of Cantabria , Santander"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carmen","family":"\u00c1lvarez-Reguera","sequence":"additional","affiliation":[{"name":"Rheumatology, Hospital Universitario Marqu\u00e9s de Valdecilla, IDIVAL, University of Cantabria , Santander"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6585-8847","authenticated-orcid":false,"given":"Jos\u00e9 Luis","family":"Hern\u00e1ndez","sequence":"additional","affiliation":[{"name":"Internal Medicine, Hospital Universitario Marqu\u00e9s de Valdecilla, IDIVAL , Santander, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Miguel \u00c1ngel","family":"Gonz\u00e1lez-Gay","sequence":"additional","affiliation":[{"name":"Rheumatology, Hospital Universitario Marqu\u00e9s de Valdecilla, IDIVAL, University of Cantabria , Santander"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2344-2285","authenticated-orcid":false,"given":"Ricardo","family":"Blanco","sequence":"additional","affiliation":[{"name":"Rheumatology, Hospital Universitario Marqu\u00e9s de Valdecilla, IDIVAL, University of Cantabria , Santander"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"name":"the Neurobeh\u00e7et Spanish Collaborative Group","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ana","family":"Blanco","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jos\u00e9 Luis","family":"Callejas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anahy","family":"Brandy-Garc\u00eda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alejandro","family":"Oliv\u00e9","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elvira","family":"D\u00edez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"\u00c1lvaro","family":"Seijas-L\u00f3pez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Concepci\u00f3n","family":"Delgado-Beltr\u00e1n","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2022,2,15]]},"reference":[{"key":"2022110207595786000_keac097-B1","first-page":"137","article-title":"Neuro-Behcet\u2019s disease \u2013 case report and review","volume":"45","author":"Tsalta-Mladenov","year":"2020","journal-title":"Acta Reumatol Port"},{"key":"2022110207595786000_keac097-B2","doi-asserted-by":"crossref","first-page":"577308","DOI":"10.1016\/j.jneuroim.2020.577308","article-title":"Rituximab as an effective therapeutic option in refractory Neuro-Beh\u00e7et syndrome","volume":"346","author":"Garcia-Estrada","year":"2020","journal-title":"J Neuroimmunol"},{"key":"2022110207595786000_keac097-B3","doi-asserted-by":"crossref","first-page":"101906","DOI":"10.1016\/j.msard.2019.101906","article-title":"Neuro-Beh\u00e7et\u2019s disease: an update on diagnosis, differential diagnoses, and treatment","volume":"39","author":"Borhani-Haghighi","year":"2020","journal-title":"Mult Scler Relat Disord"},{"key":"2022110207595786000_keac097-B4","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1007\/s11940-016-0405-6","article-title":"Beh\u00e7et\u2019s disease and nervous system involvement","volume":"18","author":"K\u00fcrt\u00fcnc\u00fc","year":"2016","journal-title":"Curr Treat Options Neurol"},{"key":"2022110207595786000_keac097-B5","doi-asserted-by":"crossref","first-page":"1306","DOI":"10.1002\/art.38351","article-title":"Long-term outcome of neuro-Beh\u00e7et\u2019s disease","volume":"66","author":"Noel","year":"2014","journal-title":"Arthritis Rheumatol"},{"key":"2022110207595786000_keac097-B6","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1016\/j.jns.2007.09.041","article-title":"Histopathology of central nervous system lesions in Beh\u00e7et\u2019s disease","volume":"267","author":"Hirohata","year":"2008","journal-title":"J Neurol Sci"},{"key":"2022110207595786000_keac097-B7","doi-asserted-by":"crossref","first-page":"1662","DOI":"10.1007\/s00415-013-7209-3","article-title":"Diagnosis and management of Neuro-Beh\u00e7et\u2019s disease: international consensus recommendations","volume":"261","author":"Kalra","year":"2014","journal-title":"J Neurol"},{"key":"2022110207595786000_keac097-B8","doi-asserted-by":"crossref","first-page":"iii108","DOI":"10.1093\/rheumatology\/keaa086","article-title":"Management of Behcet\u2019s syndrome","volume":"59","author":"Karadag","year":"2020","journal-title":"Rheumatology"},{"key":"2022110207595786000_keac097-B9","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1016\/j.msard.2018.10.117","article-title":"Which treatment strategies for polyrefractory Neuro-Beh\u00e7et disease?","volume":"27","author":"London","year":"2019","journal-title":"Mult Scler Relat Disord"},{"key":"2022110207595786000_keac097-B10","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1007\/s10067-016-3506-4","article-title":"Interleukin (IL)-1 inhibition with anakinra and canakinumab in Beh\u00e7et\u2019s disease-related uveitis: a multicenter retrospective observational study","volume":"36","author":"Fabiani","year":"2017","journal-title":"Clin Rheumatol"},{"key":"2022110207595786000_keac097-B11","doi-asserted-by":"crossref","first-page":"1619","DOI":"10.4103\/0028-3886.246252","article-title":"Focus on neuro-Beh\u00e7et\u2019s disease: a review","volume":"66","author":"Caruso","year":"2018","journal-title":"Neurol India"},{"key":"2022110207595786000_keac097-B12","first-page":"1078","article-title":"Criteria for diagnosis of Beh\u00e7et\u2019s disease","volume":"335","author":"Weichsler","year":"1990","journal-title":"Lancet"},{"key":"2022110207595786000_keac097-B13","first-page":"154","article-title":"Behcet syndrome and peripheral neuropathy as a possible new minor criterion","volume":"189","author":"Gonz\u00e1lez-Gay","year":"1991","journal-title":"Rev Clin Espanola"},{"key":"2022110207595786000_keac097-B14","first-page":"703","article-title":"Epidemiologic and clinical aspects of Beh\u00e7et\u2019s disease in a defined area of Northwestern Spain, 1988-1997","volume":"27","author":"Gonz\u00e1lez-Gay","year":"2000","journal-title":"J Rheumatol"},{"key":"2022110207595786000_keac097-B15","first-page":"275","article-title":"Anti-TNF-\u03b1 therapy in the management of severe neurosarcoidosis: a report of five cases from a single centre and literature review","volume":"32","author":"Riancho-Zarrabeitia","year":"2014","journal-title":"Clin Exp Rheumatol"},{"key":"2022110207595786000_keac097-B16","doi-asserted-by":"crossref","first-page":"1444","DOI":"10.1016\/j.ophtha.2018.02.020","article-title":"Successful optimization of adalimumab therapy in refractory uveitis due to Beh\u00e7et\u2019s disease","volume":"125","author":"Mart\u00edn-Varillas","year":"2018","journal-title":"Ophthalmology"},{"key":"2022110207595786000_keac097-B17","doi-asserted-by":"crossref","first-page":"2081","DOI":"10.1002\/art.41026","article-title":"Comparative study of infliximab versus adalimumab in refractory uveitis due to Beh\u00e7et\u2019s disease: national multicenter study of 177 cases","volume":"71","author":"Atienza-Mateo","year":"2019","journal-title":"Arthritis Rheumatol"},{"key":"2022110207595786000_keac097-B18","doi-asserted-by":"crossref","first-page":"2816","DOI":"10.3390\/jcm9092816","article-title":"Anti-IL-6 receptor tocilizumab in refractory Graves\u2019 orbitopathy: national multicenter observational study of 48 patients","volume":"9","author":"S\u00e1nchez-Bilbao","year":"2020","journal-title":"J Clin Med"},{"key":"2022110207595786000_keac097-B19","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1016\/j.semarthrit.2016.03.002","article-title":"Golimumab in refractory uveitis related to spondyloarthritis. Multicenter study of 15 patients","volume":"46","author":"Calvo-R\u00edo","year":"2016","journal-title":"Semin Arthritis Rheum"},{"key":"2022110207595786000_keac097-B20","doi-asserted-by":"crossref","first-page":"126","DOI":"10.1016\/j.semarthrit.2019.01.003","article-title":"Tocilizumab in giant cell arteritis. Observational, open-label multicenter study of 134 patients in clinical practice","volume":"49","author":"Calder\u00f3n-Goercke","year":"2019","journal-title":"Semin Arthritis Rheum"},{"key":"2022110207595786000_keac097-B21","first-page":"S54","article-title":"Tocilizumab in uveitis refractory to other biologic drugs: a study of 3 cases and a literature review","volume":"32","author":"Calvo-R\u00edo","year":"2014","journal-title":"Clin Exp Rheumatol"},{"key":"2022110207595786000_keac097-B22","doi-asserted-by":"crossref","first-page":"3906","DOI":"10.1093\/rheumatology\/keaa621","article-title":"Abatacept in interstitial lung disease associated with rheumatoid arthritis: national multicenter study of 263 patients","volume":"59","author":"Fern\u00e1ndez-D\u00edaz","year":"2020","journal-title":"Rheumatology"},{"key":"2022110207595786000_keac097-B23","first-page":"S44","article-title":"Tocilizumab in patients with Takayasu arteritis: a retrospective study and literature review","volume":"34","author":"Loricera","year":"2016","journal-title":"Clin Exp Rheumatol"},{"key":"2022110207595786000_keac097-B24","doi-asserted-by":"crossref","first-page":"856","DOI":"10.1093\/rheumatology\/kex480","article-title":"Anti-interleukin 6 receptor tocilizumab in refractory uveitis associated with Beh\u00e7et\u2019s disease: multicentre retrospective study","volume":"57","author":"Atienza-Mateo","year":"2018","journal-title":"Rheumatology"},{"key":"2022110207595786000_keac097-B25","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1016\/j.ajo.2018.12.019","article-title":"Anti-IL6-receptor tocilizumab in refractory and noninfectious uveitic cystoid macular edema: multicenter study of 25 patients","volume":"200","author":"Vegas-Revenga","year":"2019","journal-title":"Am J Ophthalmol"},{"key":"2022110207595786000_keac097-B26","doi-asserted-by":"crossref","first-page":"e3550","DOI":"10.1097\/MD.0000000000003550","article-title":"Efficacy of anti-TNF\u03b1 in severe and refractory neuro-behcet disease: an observational study","volume":"95","author":"Desbois","year":"2016","journal-title":"Medicine"},{"key":"2022110207595786000_keac097-B27","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1016\/j.jns.2008.05.002","article-title":"Effect of infliximab in progressive Neuro-Beh\u00e7et\u2019s syndrome","volume":"272","author":"Kikuchi","year":"2008","journal-title":"J Neurol Sci"},{"key":"2022110207595786000_keac097-B28","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1007\/s00296-009-1213-z","article-title":"One year study of efficacy and safety of infliximab in the treatment of patients with ocular and neurological Beh\u00e7et\u2019s disease refractory to standard immunosuppressive drugs","volume":"31","author":"Giardina","year":"2011","journal-title":"Rheumatol Int"},{"key":"2022110207595786000_keac097-B29","doi-asserted-by":"crossref","first-page":"472","DOI":"10.1016\/j.semarthrit.2014.08.004","article-title":"Tocilizumab for severe refractory neuro-Beh\u00e7et: three cases IL-6 blockade in neuro-Beh\u00e7et","volume":"44","author":"Addimanda","year":"2015","journal-title":"Semin Arthritis Rheum"},{"key":"2022110207595786000_keac097-B30","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1016\/j.jaut.2015.06.005","article-title":"Efficacy of anti-TNF alpha in severe and\/or refractory Beh\u00e7et\u2019s disease: multicenter study of 124 patients","volume":"62","author":"Vallet","year":"2015","journal-title":"J Autoimmun"},{"key":"2022110207595786000_keac097-B31","doi-asserted-by":"crossref","first-page":"e258","DOI":"10.1212\/NXI.0000000000000258","article-title":"Infliximab is a plausible alternative for neurologic complications of Beh\u00e7et disease","volume":"3","author":"Zeydan","year":"2016","journal-title":"Neurol Neuroimmunol NeuroInflammation"},{"key":"2022110207595786000_keac097-B32","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1016\/j.jaut.2017.05.002","article-title":"Ustekinumab for Beh\u00e7et\u2019s disease","volume":"82","author":"Mirouse","year":"2017","journal-title":"J Autoimmun"},{"key":"2022110207595786000_keac097-B33","doi-asserted-by":"crossref","first-page":"797","DOI":"10.1016\/j.semarthrit.2020.05.017","article-title":"Effectiveness of tocilizumab in Behcet\u2019s disease: a systematic literature review","volume":"50","author":"Akiyama","year":"2020","journal-title":"Semin Arthritis Rheum"},{"key":"2022110207595786000_keac097-B34","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1007\/s00296-020-04650-0","article-title":"Behcet\u2019s disease with peripheral nervous system involvement successfully treated with golimumab: a case report and review of the literature","volume":"41","author":"Yao","year":"2020","journal-title":"Rheumatol Int"},{"key":"2022110207595786000_keac097-B35","first-page":"S73","article-title":"Refractory neuro-Beh\u00e7et treated by tocilizumab: a case report","volume":"30(Suppl 72","author":"Urbaniak","year":"2012","journal-title":"Clin Exp Rheumatol"},{"key":"2022110207595786000_keac097-B36","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1016\/j.jocn.2016.03.020","article-title":"Neuro-Beh\u00e7et\u2019s disease presenting with tumour-like lesions and responding to rituximab","volume":"32","author":"Jade","year":"2016","journal-title":"J Clin Neurosci"},{"key":"2022110207595786000_keac097-B37","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1097\/BOR.0000000000000666","article-title":"Management of Beh\u00e7et syndrome","volume":"32","author":"Yazici","year":"2020","journal-title":"Curr Opin Rheumatol"},{"key":"2022110207595786000_keac097-B38","doi-asserted-by":"crossref","first-page":"2830","DOI":"10.3389\/fimmu.2019.02830","article-title":"Treating the different phenotypes of Beh\u00e7et\u2019s syndrome","volume":"10","author":"Bettiol","year":"2019","journal-title":"Front Immunol"},{"key":"2022110207595786000_keac097-B39","first-page":"55","article-title":"Neuro-Beh\u00e7et\u2019s disease","volume":"16","author":"Hadfield","year":"1997","journal-title":"Clin Neuropathol"},{"key":"2022110207595786000_keac097-B40","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1006\/clin.1996.4268","article-title":"Cerebrospinal fluid interleukin-6 in progressive neuro-Beh\u00e7et\u2019s syndrome","volume":"82","author":"Hirohata","year":"1997","journal-title":"Clin Immunol Immunopathol"}],"container-title":["Rheumatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/rheumatology\/advance-article-pdf\/doi\/10.1093\/rheumatology\/keac097\/42674531\/keac097.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/rheumatology\/article-pdf\/61\/11\/4427\/46747676\/keac097.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/rheumatology\/article-pdf\/61\/11\/4427\/46747676\/keac097.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,11,2]],"date-time":"2022-11-02T08:02:24Z","timestamp":1667376144000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/rheumatology\/article\/61\/11\/4427\/6528885"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,2,15]]},"references-count":40,"journal-issue":{"issue":"11","published-online":{"date-parts":[[2022,2,15]]},"published-print":{"date-parts":[[2022,11,2]]}},"URL":"https:\/\/doi.org\/10.1093\/rheumatology\/keac097","relation":{},"ISSN":["1462-0324","1462-0332"],"issn-type":[{"value":"1462-0324","type":"print"},{"value":"1462-0332","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2022,11,1]]},"published":{"date-parts":[[2022,2,15]]}}}